 Connection
Michael Szarek to Ezetimibe
This is a "connection" page, showing publications Michael Szarek has written about Ezetimibe.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.284 |
|
|
|
-
Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG. Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. J Lipid Res. 2026 May; 67(5):101028.
Score: 0.237
-
Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pecin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022 10 20; 29(14):1842-1851.
Score: 0.047
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|